ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: PP08

Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 0306

Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy

(0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0235

Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0561

Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0328

From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0312

Frontal Lobe Activation and Gait Alterations During Single- and Dual-task Walking in People with Knee Osteoarthritis: A Functional Near-infrared Spectroscopy Study

(0308–0324) Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0386

Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0170

Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group)

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0560

Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0015

Genetic Predisposition to a Positive Antinuclear Antibody Test Is Not Associated with Increased Risk of Disease

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0034

Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0715

Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0447

Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER

(0423–0459) RA – Treatments Poster I

9:00AM-11:00AM: Abstract Number: 0059

GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0057

GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis

(0040–0064) Innate Immunity Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.